European Commission Approves Darolutamide Plus ADT for Metastatic Hormone-Sensitive Prostate Cancer

/in /by

The European Commission has granted marketing authorization to darolutamide (Nubeqa) combined with androgen deprivation therapy (ADT) for treating metastatic hormone-sensitive prostate cancer (mHSPC). This approval, following a positive opinion from the European Medicines Agency in June 2025, allows darolutamide plus ADT to be used with or without docetaxel, offering clinicians greater flexibility in tailoring treatment. […]

Read more

Newsletter 29/2025

/in /by

LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! Apparently, research never fully takes a break. While most of the major news will come in the fall, we still have some interesting results this week. Stay strong and fight on! As usual, we also have a podcast if […]

Read more

Breakthrough in Cancer Immunotherapy: In Situ CAR-T Cell Generation Offers Hope for Lymphoma and Beyond

/in , , /by

A groundbreaking study led by Stanford Medicine, published in Cancer Immunology Research, has introduced a revolutionary approach to generating chimeric antigen receptor (CAR)-T cells directly inside the body, offering a promising new avenue for cancer treatment. This “in situ” method, which uses mRNA delivered via lipid nanoparticles (LNPs), successfully treated B-cell lymphoma in mice and […]

Read more